| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,752 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wentworth Kerry |
VP, Clinical, Reg, & Quality |
• – – |
2011-12-21 |
4 |
S |
$2.24 |
$7,641 |
D/D |
(3,414) |
32,067 |
|
- |
|
| Valentine Karen |
VP, General Counsel |
• – – |
2011-12-21 |
4 |
S |
$2.24 |
$5,255 |
D/D |
(2,348) |
14,051 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-12-21 |
4 |
S |
$2.24 |
$6,909 |
D/D |
(3,087) |
48,551 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2011-12-21 |
4 |
S |
$2.24 |
$4,420 |
D/D |
(1,975) |
15,972 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-12-01 |
4 |
A |
$2.57 |
$13,199 |
D/D |
5,130 |
926,466 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-11-01 |
4 |
A |
$2.87 |
$13,200 |
D/D |
4,603 |
921,321 |
|
- |
|
| Wentworth Kerry |
VP, Clinical, Reg & Quality |
• – – |
2011-10-26 |
4 |
A |
$2.70 |
$1,877 |
D/D |
695 |
35,481 |
|
- |
|
| Valentine Karen |
VP, General Counsel |
• – – |
2011-10-26 |
4 |
A |
$2.70 |
$1,123 |
D/D |
416 |
16,399 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2011-10-26 |
4 |
A |
$2.70 |
$1,123 |
D/D |
416 |
17,915 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-10-26 |
4 |
A |
$2.70 |
$1,688 |
D/D |
625 |
51,638 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-10-26 |
4 |
A |
$2.70 |
$3,750 |
D/D |
1,389 |
916,718 |
|
- |
|
| Rothwell Timothy G |
Director |
– • – |
2011-10-03 |
4 |
A |
$3.80 |
$9,249 |
D/D |
2,434 |
7,389 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-10-03 |
4 |
A |
$3.33 |
$13,197 |
D/D |
3,966 |
915,329 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-09-30 |
4 |
B |
$2.99 |
$49,768 |
D/D |
16,666 |
911,363 |
2.74 |
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2011-09-13 |
4 |
A |
$0.55 |
$1,834 |
D/D |
3,334 |
104,995 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2011-09-12 |
4/A |
A |
$0.55 |
$1,834 |
D/D |
3,334 |
104,995 |
|
- |
|
| Valentine Karen |
VP, General Counsel |
• – – |
2011-09-12 |
4 |
A |
$0.55 |
$1,834 |
D/D |
3,334 |
95,902 |
|
- |
|
| Wentworth Kerry |
VP, Clinical, Reg & Quality |
• – – |
2011-09-12 |
4 |
A |
$0.55 |
$2,750 |
D/D |
5,000 |
208,716 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-09-12 |
4 |
A |
$0.55 |
$2,750 |
D/D |
5,000 |
306,079 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-09-12 |
4 |
A |
$0.55 |
$8,250 |
D/D |
15,000 |
5,368,186 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-09-01 |
4 |
A |
$0.57 |
$13,200 |
D/D |
23,247 |
5,353,186 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-08-16 |
4 |
B |
$0.51 |
$1,096,998 |
D/D |
2,150,976 |
5,329,939 |
2.74 |
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-08-01 |
4 |
A |
$0.79 |
$13,199 |
D/D |
16,687 |
3,178,963 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-07-27 |
4 |
A |
$0.79 |
$120,417 |
D/D |
152,427 |
3,162,276 |
|
- |
|
| Wentworth Kerry |
VP, Clinical, Reg & Quality |
• – – |
2011-07-26 |
4 |
A |
$0.79 |
$3,291 |
D/D |
4,166 |
203,716 |
|
- |
|
537 Records found
|
|
Page 13 of 22 |
|
|
